Two new drugs join forces with chemo to tackle tough lymphoma

NCT ID NCT06977711

Recruiting now Disease control Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether adding two drugs—loncastuximab and roflumilast—to the standard R-CHOP chemotherapy regimen can safely treat people with untreated, high-risk diffuse large B-cell lymphoma (DLBCL). The study enrolls about 10 adults with this aggressive lymphoma who have not received prior therapy. Researchers will monitor side effects and measure how well the tumors respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: loncastuximab, roflumilast, rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone
What this could lead to: If successful, this combination could improve outcomes for people with high-risk DLBCL, potentially leading to a more effective first-line treatment.
What could go wrong: This is a very early phase 1 trial with only 10 participants, so safety and effectiveness are not yet established. Adding more drugs may increase side effects without improving results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

University Hospital System
RECRUITING

San Antonio, Texas, 78228, United States
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.